Actinium Pharmaceuticals (ATNM) FCF Margin (2021 - 2026)

Actinium Pharmaceuticals (ATNM) posted quarterly FCF Margin of 7027.78% for Q3 2025, up 45.36% quarter-over-quarter from 12862.22% in Q3 2022.

Actinium Pharmaceuticals (ATNM) FCF Margin (2021 - 2026) Analysis & Trends

Actinium Pharmaceuticals (ATNM) has reported FCF Margin for 3 consecutive years, with 7027.78% the latest figure, recorded in Q3 2025.

In Q3 2025, FCF Margin changed N/A year-over-year to 7027.78%; the TTM figure through Dec 2025 stood at 18207.41% (changed N/A YoY), while the FY2025 annual figure was 27426.67%, changed N/A from the prior year.
FCF Margin rose to 7027.78% in Q3 2025 per ATNM's latest filing, from 12862.22% in the prior quarter.
Across five years, FCF Margin topped out at 61440.0% in Q2 2022 and bottomed at 21965.22% in Q4 2021.
Historically, FCF Margin has averaged 1735.95% across 3 years, with a median of 2086.85% in 2021.
On a YoY basis, FCF Margin climbed as much as 6318624 bps in 2022 and fell as far as 1043475 bps in 2022.
Actinium Pharmaceuticals' FCF Margin stood at 21965.22% in 2021, then surged by 41 bps to 12862.22% in 2022, then soared by 45 bps to 7027.78% in 2025.
Business Quant data shows ATNM's FCF Margin at 7027.78% in Q3 2025, 12862.22% in Q3 2022, and 61440.0% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.96 Bn	132.11 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	86.79 Bn	78.79 Bn	3.93 Bn	13.35%
3	Argenx Se	65.22 Bn	60.03 Bn	1.37 Bn	-
4	Moderna	60.20 Bn	55.06 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	42.19 Bn	37.09 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.43 Bn	28.12 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.65 Bn	10.26 Bn	668.28 Mn	41.07%
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.16 Bn	26.32 Bn	-	70.82%
10	Actinium Pharmaceuticals	35.74 Mn	35.74 Mn	-	-16.16%

Download Data